The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study (ACER/AMN)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study - a Prospective Observational Cohort Study|
- Recurrence [ Time Frame: 6-60 months ] [ Designated as safety issue: No ]Follow up colonoscopies as per standard of care for 6 - 60 months noting and treating any recurrence.
- Cancer prediction [ Time Frame: Initial procedure ] [ Designated as safety issue: No ]By properly assessing the lesion it is hoped that we will be able to provide the greater Gastroenterology community with a tool which can be used to properly identify benign and cancerous lesions to decrease the number of benign lesions being referred to surgery.
- Improved Endoscopic Resection [ Time Frame: 0-60 months ] [ Designated as safety issue: No ]By assessing the lesion at resection and following up with standard of care colonoscopies it is anticipated that there will be an improved endoscopic resection efficacy therefore reducing the risk of recurrence.
|Study Start Date:||January 2014|
|Estimated Study Completion Date:||January 2034|
|Estimated Primary Completion Date:||December 2024 (Final data collection date for primary outcome measure)|
Endoscopic Mucosal Resection
Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
|Procedure: Endoscopic Mucosal Resection|
The Australian Colonic Endoscopic Mucosal Resection study (ACE), is a multicentre prospective observational study which examined WF-EMR of colonic AMN (Ethics approval No. HREC JH/TG 2008/9/6.1(2858)). This project now has an extensive dataset from 8 leading colonic endoscopic resection centres in Australia on more than 1500 lesions resected over 4 years since June 2008.
The ACE study has been successful in addressing several aspects of the resection of AMN, resulting in several high profile papers in internationally recognised journals. The collection of this data has produced robust information on the efficacy of the procedure4, recurrence rates7, bleeding complications8 and mortality when compared to surgery5. Single centre analysis of the ACE dataset at Westmead has also allowed insights into how to refine the procedure to improve outcomes. The target sign is now a recognised indication for the placement of clips to prevent perforation9, CO2 insufflation for WF-EMR has been shown to be superior to air insufflation10 and succinylated gelatin (Gelofusine®) has been shown to be superior to normal saline as a submucosal lifting agent11.
There remain a number of unanswered questions regarding the endoscopic resection of large sessile lesions and expanding the ACE dataset in a new cohort of patients will allow these to be addressed. Enhancing the prediction of submucosal invasive cancer, advanced lesion classification, refinement of the assessment of deep injury, submucosal injectate constituents, the optimum electrosurgical resection methods, prevention and prophylaxis of bleeding, and subtype analyses of the different histological groups comprising AMN will be examined.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02000141
|Contact: Rebecca Sonson, BN||98455555 ext email@example.com|
|Contact: Michael Bourke, MBBS||98455555 ext 59779|
|Australia, New South Wales|
|Westmead Endoscopy Unit||Recruiting|
|Westmead, New South Wales, Australia, 2145|
|Contact: Rebecca Sonson, BN 98455555 ext 59779 firstname.lastname@example.org|
|Sub-Investigator: Nicholas Burgess, MBBS|
|Principal Investigator: Michael Bourke, MBBS|
|Sub-Investigator: Eric Lee, MBBS|
|Sub-Investigator: Stephen Williams, MBBS|
|Principal Investigator:||Michael Bourke, MBBS||South West Sydney Area Health Service|